KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 73,649 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 73,649 shares of the company’s stock in a transaction on Friday, February 7th. The shares were acquired at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the acquisition, the insider now directly owns 5,086,445 shares in the company, valued at $47,253,074.05. This represents a 1.47 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.14 per share, with a total value of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $9.22 per share, for a total transaction of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Up 0.9 %

Shares of KALV stock opened at $9.27 on Wednesday. The stock has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The firm’s 50 day moving average price is $8.75 and its two-hundred day moving average price is $10.58.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of KalVista Pharmaceuticals by 67.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $126,000. SG Americas Securities LLC bought a new stake in shares of KalVista Pharmaceuticals in the third quarter worth $153,000. Quest Partners LLC bought a new stake in KalVista Pharmaceuticals during the third quarter valued at $175,000. Finally, The Manufacturers Life Insurance Company increased its stake in KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on KALV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price on the stock. Bank of America began coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).